Emil D Kakkis sold $495k of RARE
President & CEO at Ultragenyx Pharmaceutical Inc.. 11,727 shares at an average of $42.23, traded Dec 30, 2024, filed Dec 31, 2024.
Score components
- +25RoleCEO
- +18Trade size$495k at market
- 0Share of holdings soldSold 0.5% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-141485, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 30, 2024 | SOpen-market sale Common Stockindirect: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200910b5-1 | -11,727 | $42.23 | $495k | 2,183,985 | Dec 31, 2024 |
Related signals
Other insiders at Ultragenyx Pharmaceutical Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $17k 1,283 shares | -2% | |
| 15Weak | RAREsell Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $2,252 161 shares | -0% | |
| 9Weak | Ultragenyx Pharmaceutical Inc. | Corazon (Corsee) D. Sanders director | $90k 2,405 shares | -14% | |
| 20Weak | RAREsell Ultragenyx Pharmaceutical Inc. | Eric Crombez EVP and Chief Medical Officer | $29k 762 shares | -1% | |
| 45Moderate | Ultragenyx Pharmaceutical Inc. | Howard Horn Chief Financial Officer | $72k 1,785 shares | -2% | |
| 51Moderate | Ultragenyx Pharmaceutical Inc. | Eric Crombez EVP and Chief Medical Officer | $377k 8,945 shares | -11% | |
| 55Moderate | Ultragenyx Pharmaceutical Inc. | Erik Harris EVP & Chief Commercial Officer | $636k 15,103 shares | -15% | |
| 36Weak | Ultragenyx Pharmaceutical Inc. | Theodore Alan Huizenga SVP, Chief Accounting Officer | $41k 967 shares | -2% | |
| 45Moderate | Ultragenyx Pharmaceutical Inc. | Emil D Kakkis President & CEO | $4.2M 98,434 shares | -5% | |
| 43Moderate | Ultragenyx Pharmaceutical Inc. | Thomas Richard Kassberg CBO & EVP | $254k 6,028 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.